Vikki Roberts
Physician Assistant · Hickory, NCNPI 1871524306
Payments from drug & device makers
Across 640 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Neurocrine Biosciences, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Alkermes, Inc.$1K
- plus $3K from 19 others
What the payments were for
- Food & beverage$10,04798%
- Education$1762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 133 | $1,328 |
| Neurocrine Biosciences, Inc. | 64 | $1,277 |
| Otsuka America Pharmaceutical, Inc. | 66 | $1,147 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 79 | $1,141 |
| Teva Pharmaceuticals USA, Inc. | 59 | $1,130 |
| Alkermes, Inc. | 57 | $1,055 |
| Sunovion Pharmaceuticals Inc. | 45 | $690 |
| Vanda Pharmaceuticals Inc. | 24 | $498 |
| Johnson & Johnson | 28 | $453 |
| Indivior Inc. | 22 | $392 |
| Almatica Pharma LLC | 16 | $291 |
| E.r. Squibb & Sons, L.L.C. | 12 | $230 |
| Noven Therapeutics, LLC | 9 | $130 |
| Lundbeck LLC | 6 | $121 |
| Corium, LLC | 5 | $84 |
| Axsome Therapeutics, Inc. | 3 | $48 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| VYNE Pharmaceuticals Inc. | 2 | $38 |
| Luye Pharma (USA) Ltd. | 1 | $26 |
| Eisai Inc. | 2 | $26 |
| Medtronic | 1 | $22 |
| Abbott | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Noven Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$228
How this compares
$10,224 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 87 | $708,080 |
| Invega SustennaPaliperidone Palmitate | 160 | $557,614 |
| VraylarCariprazine Hcl | 165 | $262,037 |
| AristadaAripiprazole Lauroxil | 73 | $240,760 |
| RexultiBrexpiprazole | 134 | $230,134 |
| AustedoDeutetrabenazine | 18 | $180,428 |
| CaplytaLumateperone Tosylate | 101 | $174,907 |
| LybalviOlanzapine/Samidorphan Malate | 68 | $113,942 |
| Invega TrinzaPaliperidone Palmitate | 13 | $106,750 |
| Abilify AsimtufiiAripiprazole | 18 | $103,653 |
| Abilify MaintenaAripiprazole | 35 | $97,918 |
| UzedyRisperidone | 13 | $48,903 |
| TrintellixVortioxetine Hydrobromide | 44 | $25,702 |
| Loreev XrLorazepam | 38 | $17,669 |
| FanaptIloperidone | 12 | $16,106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,277 | $708,08087 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $453 | $664,363173 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Asimtufii, Abilify Maintena | $1,147 | $431,704187 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,055 | $354,701141 claims |
| AbbVieVraylar | $1,328 | $262,037165 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy | $1,130 | $229,33031 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,141 | $174,907101 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $14 | $25,70244 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $291 | $22,280272 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $498 | $16,10612 claims |
| Axsome Therapeutics, Inc.Auvelity | $48 | $15,40712 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $39 | $6,03112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Hickory
- Sarah PadgettHickory$29K
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.